Genome Web Breaking News
- Cancer Genetics Q2 Revenues Drop 5 Percent
- IsoPlexis Partnering With Columbia to Study Immune Response to SARS-CoV-2
- Pro-Lab Diagnostics Nabs FDA Emergency Use Authorization for Molecular SARS-CoV-2 Test
- HHS Invests $6.5M in Aegis Sciences, Sonic Healthcare USA to Expand Coronavirus Testing Capacity
- Myriad Genetics Q4 Revenues Plummet 57 Percent on Coronavirus Pandemic Pressures
Stat
- STAT Plus: Medicaid beneficiaries sue Texas health agency for restricting access to hepatitis C medicines
- STAT Plus: CureVac’s value soars after IPO, as Covid-19 vaccine manufacturers become biotech’s hottest companies
- STAT Plus: Up and down the ladder: The latest comings and goings
- STAT Plus: Pharmalittle: Governments race to acquire Covid-19 vaccines; top Russian doctor quits over vaccine ethics
- STAT Plus: Johnson & Johnson invests in Thirty Madison, signaling the resilience of pharma’s interest in health tech
Xconomy news
- Bio Roundup: Seres Soars, MesoBlast Vote, Duchenne Decision & More
- With FDA Nod, NS Pharma Duchenne Drug Becomes Sarepta Competitor
- Perceptive Advisors’ LianBio Inks Deals With BridgeBio, MyoKardia
- F2G Lands $60M for a New Tack on Taking Out Rare Fungal Infections
- Pfizer’s Bourla: There’s Coronavirus Vaccine Pressure, But It’s Not Political
Fierce Biotech
- NIH study shows multifocal contact lenses can slow down childhood nearsightedness
- FDA clears RapidAI’s occlusion-spotting stroke software for CT scans
- Philips deploys hospital monitor kits to ramp-up ICU capacity against COVID-19
- CureVac banks $213M IPO to push COVID-19 vaccine, boost manufacturing
- Chutes & Ladders—WuXi taps veteran operations head Dong to lead new vaccines unit
Fierce Medical Devices
- NIH study shows multifocal contact lenses can slow down childhood nearsightedness
- FDA clears RapidAI’s occlusion-spotting stroke software for CT scans
- Philips deploys hospital monitor kits to ramp-up ICU capacity against COVID-19
- Atomwise raises $123M to expand AI-powered drug design efforts
- Thermo Fisher’s $12.5B deal for Qiagen falls through, as COVID-19 test demand lights new path forward